HOME >> BIOLOGY >> NEWS
Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane

imen are impressive in this population of taxane-refractory patients," said Dr. Joanne Blum, Principal Investigator of the study. "Abraxane differentiates itself from other taxanes because it enables us to administer more cancer-fighting paclitaxel to the patient without an increase in side effects one might expect to see with currently available taxane therapies."

"It appears that Abraxane allows for more cancer-fighting drug to be given to a patient, more of that drug to actually reach the tumor site in the body, and more of the drug to get inside of the tumor to fight cancer cells."

The tolerability of the weekly regimen was demonstrated by the finding of <1 percent grade 4 febrile neutropenia and no grade 4 non-hematological toxicities. Grade 3 associated toxicities were few, with <4 percent sensory neuropathy, <3 percent fatigue, <1 percent edema, <1 percent tearing, and no Grade 3 nail changes, myalgia, arthralgia, hypersensitivity or flushing.

A New Drug Application for Abraxane is currently under review by the U.S. Food and Drug Administration. Abraxane is an investigational drug that uses nanoparticle technology to combine paclitaxel long been considered one of the most effective cancer drugs with the natural protein "transporter" albumin, avoiding the need for toxic solvents and detergents like those used in Taxol and Taxotere. By eliminating these toxic elements, patients treated with Abraxane do not typically need routine premedications.

The previously reported pivotal Phase III trial demonstrated superior response rate and time to tumor progression in metastatic breast cancer patients versus Taxol.


'"/>

Contact: Melyssa Weible
MWeible@healthstarpr.com
646-328-1457
HealthStar PR
14-Jun-2004


Page: 1 2

Related biology news :

1. Breastfeeding decreases infant mortality
2. Breast cancer study suggests role for tissue in carcinogenesis
3. Breast self examination increases womens concerns but has no effect on mortality
4. Breast cancer follow-ups no longer guess-work thanks to new physics research
5. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
6. The 4th European Breast Cancer Conference (EBCC4)
7. Breast cancer susceptibility genes play role in DNA repair
8. Breast cancer can be reversed in laboratory mice, scientists report
9. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
10. Breast fluid a better option for detecting cancer
11. Breastfeeding may compensate for harmful effects of smoking during pregnancy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... on building awareness and solutions for glioblastoma—the most common and aggressive adult brain ... Lisa Haile, JD, PhD. Senior Fellows are charged with supporting the organization’s initiatives ...
(Date:6/25/2020)... Mass. (PRWEB) , ... June 24, 2020 , ... ... of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, ... for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This ...
(Date:6/23/2020)... TORONTO (PRWEB) , ... June 22, 2020 , ... The ... time. Typically, ligand binding assays (LBA) have dominated this area. However, the use of ... several years. , This now necessitates the question “How do you choose which approach ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
(Date:7/18/2020)... ... 2020 , ... After research model surgery and catheter implantation, the long journey ... the beginning of a successful study, while protecting and accessing the catheter or device ... of Surgery from Envigo in a live webinar on Wednesday, ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , ... sciences and food industries, is pleased to announce that Charles Galea has joined ... Development. , Charles is an accomplished and results-driven sales executive with over 10 ...
(Date:7/10/2020)... , ... July 09, 2020 , ... ... 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining ... research team led by Dr MA has been using the zebrafish model to ...
Breaking Biology Technology:
Cached News: